Joseph Negri

TL;DR: In vitro evidence for induction of MM cell death and therapeutic window for the anti-MM effect of VE465, its ability to overcome protective effect of BM-derived cytokines, and the clearly distinct pattern of molecular sequelae of Ve465 compared to several other agents in the current anti- MM therapeutic armamentarium suggest that Aurora kinase inhibition represents an intriguing novel targeted treatment strategy in MM.

TL;DR: In this paper, Dasatinib can be administered alone or in combination with a second anti-neoplastic agent such as dexamethasone or bortezomib.

TL;DR: Preclinical studies on the anti-MM activity of the selective CDK1/2 small molecule inhibitor NVP-LCQ195/AT9311 show functional inhibition of proteins involved in cell cycle regulation remains an attractive approach for the treatment of multiple myeloma.

TL;DR: CS-BLI is able to overcome the key limitations that have precluded the establishment of high-throughput screening for testing new drugs in tumor-stroma co-cultures and provides sensitive detection of viable MM cells, both in the presence and absence of BMSCs.

TL;DR: The dual PI3K/mTOR inhibitor NVP-BEZ235 induces MM cell killing at sub-μM concentrations, with significantly higher sensitivity of MM cells compared to normal tissues, suggesting that this kinase inhibitor merits further consideration for possible testing as treatment option for MM patients.